Lafora disease is a rare, fatal genetic disorder affecting the brain, with limited treatment options and severe symptoms.

Lupin has launched generic Tolvaptan tablets for kidney disorder treatment in the US, providing increased access to ...

Netherlands biotech Azafaros is poised to start phase 3 trials of its lead drug for a trio of rare lysosomal storage ...

Tolvaptan tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant ...

Mumbai: Global pharma major Lupin Limited has announced the launch of Tolvaptan Tablets, 15 mg, 30 mg, 45 mg, 60 mg, and 90 ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor ...

Pharma major Lupin Ltd on Tuesday said it has launched the Tolvaptan tablets used to slow kidney function decline in the US ...

Imbalances in metal ions may play a role in the development of diabetes and its complications. Can they be a novel target for ...

Consultant Neurologist Professor Tim Lynch acknowledged “there is something” that is increasing the frequency of the disease.

A baby known as KJ is the first person in the world to receive a customized CRISPR therapy designed to fix a specific ...

Interim data from ENERGY 3 trial highlight INZ-701's potential to modify disease course in ENPP1 Deficiency, with sustained ...